Document Detail


Exercise testing in late-onset glycogen storage disease type II patients undergoing enzyme replacement therapy.
MedLine Citation:
PMID:  23182645     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Enzyme replacement therapy (ERT) has recently became available for patients with glycogen storage disease type II. Previous studies have demonstrated clinical efficacy of enzyme replacement therapy, however, data on physiological variables related to exercise tolerance are scarce. Four glycogen storage disease type II late-onset patients (45 ± 6 years) performed an incremental exercise on a cycle ergometer, up to voluntary exhaustion, before (BEFORE) and after 12 months of ERT (AFTER). Peak workload, oxygen uptake, heart rate, cardiac output (by impedance cardiography) and vastus lateralis oxygenation indices (by continuous-wave near-infrared spectroscopy, NIRS) were determined. Peak workload and oxygen uptake values significantly increased during ERT (54 ± 30 vs. 63 ± 31 watt, and 17.2 ± 4.4 vs. 19.7 ± 3.5 ml/kg/min, respectively, in BEFORE vs. AFTER). On the other hand, for both peak cardiac output (12.3 ± 5.3 vs. 14.8 ± 4.5L/min) and the NIRS-determined peak skeletal muscle fractional O(2) extraction, expressed as a percentage of the maximal values during a transient limb ischemia (30 ± 39% vs. 38 ± 28%), the observed increases were not statistically significant. Our findings suggest that in glycogen storage disease type II patients enzyme replacement therapy is associated with a mild improvement of exercise tolerance. The findings need to be validated during a longer follow-up on a larger group of patients.
Authors:
Mauro Marzorati; Simone Porcelli; Giuseppe Bellistri; Lucia Morandi; Bruno Grassi
Related Documents :
3574045 - Heat acclimatization during summer running in the northeastern united states.
3412865 - Recovery heat production of isolated rabbit papillary muscle at 20 degrees c.
12834575 - Fluid balance and endurance exercise performance.
24809305 - Moderate intensity exercise is associated with decreased angiotensin-converting enzyme,...
7957455 - What is the better formulation of microencapsulated potassium chloride?
1620385 - Effects of heat-exercise stress, nbc clothing, and pyridostigmine treatment on psychomo...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Neuromuscular disorders : NMD     Volume:  22 Suppl 3     ISSN:  1873-2364     ISO Abbreviation:  Neuromuscul. Disord.     Publication Date:  2012 Dec 
Date Detail:
Created Date:  2012-11-27     Completed Date:  2013-03-12     Revised Date:  2014-03-19    
Medline Journal Info:
Nlm Unique ID:  9111470     Medline TA:  Neuromuscul Disord     Country:  England    
Other Details:
Languages:  eng     Pagination:  S230-4     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier B.V. All rights reserved.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Age of Onset
Cardiac Output / physiology
Enzyme Replacement Therapy* / methods
Exercise Test / methods
Exercise Tolerance / physiology*
Female
Follow-Up Studies
Glycogen Storage Disease Type II / physiopathology*,  therapy*
Heart Rate / physiology
Humans
Male
Middle Aged
Oxygen Consumption / physiology
Treatment Outcome
alpha-Glucosidases / therapeutic use*
Grant Support
ID/Acronym/Agency:
GUP08007//Telethon
Chemical
Reg. No./Substance:
EC 3.2.1.20/alpha-Glucosidases
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Fatigue and exercise intolerance in mitochondrial diseases. Literature revision and experience of th...
Next Document:  Chronic Fatigue Syndrome (CFS) and Cancer Related Fatigue (CRF): two "fatigue" syndromes with overla...